LON:SN - Smith & Nephew Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 1,783
  • Forecasted Upside: 15.07 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,549.50
▼ -1.5 (-0.10%)
1 month | 3 months | 12 months
Get New Smith & Nephew Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 1,783
▲ +15.07% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Smith & Nephew in the last 3 months. The average price target is GBX 1,783, with a high forecast of GBX 1,985 and a low forecast of GBX 1,423. The average price target represents a 15.07% upside from the last price of GBX 1,549.50.

Buy

The current consensus among 8 contributing investment analysts is to buy stock in Smith & Nephew. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/25/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
9/20/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/9/2021Credit Suisse GroupUpgradeOutperformGBX 1,560 ➝ GBX 1,805
i
5/18/2021Shore CapitalReiterated RatingHold
i
4/29/2021Shore CapitalReiterated RatingHold
i
4/20/2021Berenberg BankReiterated RatingBuyGBX 1,985
i
3/2/2021Shore CapitalReiterated RatingHold
i
2/23/2021JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,563 ➝ GBX 1,423
i
2/12/2021Berenberg BankReiterated RatingBuyGBX 2,005
i
1/21/2021BarclaysLower Price TargetOverweightGBX 1,900 ➝ GBX 1,875
i
1/12/2021JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,438
i
11/2/2020Berenberg BankLower Price TargetBuyGBX 2,090 ➝ GBX 1,975
i
10/27/2020Shore CapitalReiterated RatingSell
i
7/30/2020Morgan StanleyLower Price TargetOverweightGBX 1,950 ➝ GBX 1,940
i
7/30/2020Berenberg BankLower Price TargetBuyGBX 2,150 ➝ GBX 2,090
i
7/30/2020Credit Suisse GroupLower Price TargetNeutralGBX 1,685 ➝ GBX 1,675
i
7/30/2020JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,633 ➝ GBX 1,553
i
7/29/2020Shore CapitalReiterated RatingSell
i
7/22/2020Credit Suisse GroupReiterated RatingNeutral
i
7/20/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
7/10/2020Berenberg BankLower Price TargetBuyGBX 2,165 ➝ GBX 2,150
i
7/9/2020Morgan StanleyLower Price TargetBuyGBX 2,165 ➝ GBX 2,150
i
7/1/2020Shore CapitalReiterated RatingSell
i
6/23/2020UBS GroupReiterated RatingNeutral
i
6/18/2020CitigroupLower Price TargetNeutralGBX 1,700 ➝ GBX 1,670
i
6/4/2020Morgan StanleyUpgradeOverweightGBX 1,990 ➝ GBX 1,950
i
5/15/2020Credit Suisse GroupLower Price TargetNeutralGBX 1,825 ➝ GBX 1,685
i
5/7/2020Berenberg BankBoost Price TargetBuyGBX 2,135 ➝ GBX 2,165
i
5/7/2020JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,658 ➝ GBX 1,633
i
5/6/2020Shore CapitalReiterated RatingSell
i
4/28/2020Jefferies Financial GroupLower Price TargetBuyGBX 2,160 ➝ GBX 1,800
i
4/17/2020Berenberg BankReiterated RatingBuy
i
4/14/2020CitigroupDowngradeNeutralGBX 2,250 ➝ GBX 1,700
i
3/31/2020UBS GroupReiterated RatingNeutral
i
3/31/2020JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,926 ➝ GBX 1,658
i
3/30/2020Sanford C. BernsteinDowngradeMarket Perform
i
3/30/2020Shore CapitalReiterated RatingSell
i
3/26/2020Berenberg BankLower Price TargetBuyGBX 2,335 ➝ GBX 2,135
i
2/26/2020UBS GroupBoost Price TargetNeutralGBX 1,800 ➝ GBX 1,860
i
2/25/2020Berenberg BankBoost Price TargetBuyGBX 2,325 ➝ GBX 2,335
i
2/21/2020JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,711 ➝ GBX 1,926
i
2/20/2020Shore CapitalReiterated RatingSell
i
2/17/2020UBS GroupReiterated RatingNeutral
i
2/12/2020Berenberg BankBoost Price TargetBuyGBX 2,185 ➝ GBX 2,325
i
2/5/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
1/24/2020Shore CapitalReiterated RatingSell
i
1/21/2020Jefferies Financial GroupLower Price TargetBuyGBX 2,200 ➝ GBX 2,160
i
1/15/2020The Goldman Sachs GroupLower Price TargetNeutralGBX 1,695 ➝ GBX 1,670
i
12/5/2019Berenberg BankReiterated RatingBuy
i
11/21/2019CitigroupInitiated CoverageBuy
i
11/13/2019The Goldman Sachs GroupBoost Price TargetNeutralGBX 1,685 ➝ GBX 1,695
i
11/8/2019Shore CapitalReiterated RatingSell
i
11/4/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,814 ➝ GBX 1,711
i
11/4/2019Credit Suisse GroupLower Price TargetNeutralGBX 1,770 ➝ GBX 1,725
i
11/1/2019Berenberg BankLower Price TargetBuyGBX 2,185
i
10/31/2019Shore CapitalReiterated RatingSell
i
10/28/2019UBS GroupReiterated RatingNeutralGBX 1,830 ➝ GBX 1,800
i
10/21/2019Berenberg BankReiterated RatingBuyGBX 2,250
i
10/21/2019Shore CapitalReiterated RatingSell
i
10/4/2019Berenberg BankLower Price TargetBuyGBX 2,250
i
8/6/2019UBS GroupBoost Price TargetNeutralGBX 1,730 ➝ GBX 1,830
i
7/31/2019Shore CapitalReiterated RatingSell
i
7/29/2019UBS GroupReiterated RatingNeutral
i
7/22/2019UBS GroupBoost Price TargetNeutralGBX 1,455 ➝ GBX 1,730
i
7/12/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
i
6/10/2019Shore CapitalDowngradeSell
i
5/9/2019JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,689 ➝ GBX 1,758
i
5/2/2019UBS GroupReiterated RatingNeutralGBX 1,455
i
4/26/2019Berenberg BankReiterated RatingHoldGBX 1,475
i
4/25/2019Credit Suisse GroupReiterated RatingNeutral
i
3/14/2019UBS GroupReiterated RatingNeutral
i
2/11/2019JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,477 ➝ GBX 1,516
i
2/11/2019The Goldman Sachs GroupBoost Price TargetNeutralGBX 1,400 ➝ GBX 1,440
i
2/8/2019BNP ParibasDowngradeNeutralGBX 1,475 ➝ GBX 1,525
i
2/8/2019Credit Suisse GroupBoost Price TargetNeutralGBX 1,330 ➝ GBX 1,390
i
2/8/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
i
1/28/2019UBS GroupBoost Price TargetNeutralGBX 1,340 ➝ GBX 1,390
i
1/8/2019JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,477
i
1/2/2019JPMorgan Chase & Co.DowngradeNeutralGBX 1,477
i
12/10/2018Morgan StanleyUpgradeOverweightGBX 1,457 ➝ GBX 1,692
i
12/10/2018Deutsche Bank AktiengesellschaftUpgradeHoldGBX 1,200 ➝ GBX 1,350
i
11/2/2018Berenberg BankBoost Price TargetHoldGBX 1,370 ➝ GBX 1,475
i
10/26/2018UBS GroupReiterated RatingNeutral
i
10/16/2018HSBCDowngradeHoldGBX 1,400 ➝ GBX 1,500
i
10/5/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
8/8/2018UBS GroupDowngradeNeutralGBX 1,470 ➝ GBX 1,340
i
7/30/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
7/26/2018Numis SecuritiesBoost Price TargetAddGBX 1,350 ➝ GBX 1,480
i
7/20/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
7/3/2018Deutsche Bank AktiengesellschaftReiterated RatingSell
i
5/14/2018Berenberg BankReiterated RatingHoldGBX 1,370
i
5/8/2018UBS GroupLower Price TargetBuyGBX 1,550 ➝ GBX 1,470
i
5/4/2018Deutsche Bank AktiengesellschaftDowngradeSell
i
5/3/2018Jefferies Financial GroupReiterated RatingBuyGBX 1,515
i
4/25/2018JPMorgan Chase & Co.Reiterated RatingOverweight
i
4/24/2018Credit Suisse GroupReiterated RatingNeutralGBX 1,290
i
4/17/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,315 ➝ GBX 1,309.50
i
4/12/2018Jefferies Financial GroupReiterated RatingBuy
i
4/5/2018JPMorgan Chase & Co.Boost Price TargetOverweightGBX 1,411 ➝ GBX 1,463
i
3/26/2018HSBCUpgradeBuyGBX 1,320 ➝ GBX 1,530
i
2/13/2018Morgan StanleyLower Price TargetEqual weightGBX 1,558 ➝ GBX 1,457
i
2/9/2018Credit Suisse GroupBoost Price TargetNeutralGBX 1,285 ➝ GBX 1,290
i
2/7/2018JPMorgan Chase & Co.Reiterated RatingOverweightGBX 1,411
i
2/1/2018JPMorgan Chase & Co.Reiterated RatingOverweightGBX 1,411
i
1/25/2018JPMorgan Chase & Co.UpgradeOverweightGBX 1,369 ➝ GBX 1,411
i
11/13/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,382 ➝ GBX 1,369
i
11/6/2017Jefferies Financial GroupReiterated RatingBuyGBX 1,515
i
11/6/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,382
i
11/3/2017Berenberg BankReiterated RatingHoldGBX 1,340 ➝ GBX 1,340
i
10/23/2017Deutsche Bank AktiengesellschaftBoost Price TargetHoldGBX 1,200 ➝ GBX 1,315
i
10/19/2017JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,361 ➝ GBX 1,382
i
10/13/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy
i
10/12/2017Jefferies Financial GroupReiterated RatingBuyGBX 1,515
i
10/12/2017CitigroupReiterated RatingSellGBX 1,160
i
10/10/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,361
i
10/6/2017CitigroupReiterated RatingSellGBX 1,160
i
9/11/2017The Goldman Sachs GroupReiterated RatingNeutralGBX 1,380
i
7/31/2017JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,280 ➝ GBX 1,361
i
7/28/2017Credit Suisse GroupReiterated RatingNeutralGBX 1,280
i
7/28/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,200
i
7/28/2017Jefferies Financial GroupBoost Price TargetBuyGBX 1,350 ➝ GBX 1,515
i
7/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,280
i
7/20/2017Credit Suisse GroupReiterated RatingNeutralGBX 1,200
i
7/18/2017Berenberg BankReiterated RatingHoldGBX 1,300
i
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,200
i
7/10/2017CitigroupReiterated RatingSellGBX 1,160
i
6/30/2017The Goldman Sachs GroupReiterated RatingNeutralGBX 1,380
i
6/22/2017CitigroupReiterated RatingSellGBX 1,160
i
5/15/2017Morgan StanleyReiterated RatingOverweight
i
5/15/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,345 ➝ GBX 1,280
i
5/15/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,200
i
5/15/2017Credit Suisse GroupBoost Price TargetNeutralGBX 1,160 ➝ GBX 1,200
i
5/8/2017Morgan StanleyReiterated RatingOverweight
i
5/8/2017Credit Suisse GroupBoost Price TargetNeutralGBX 1,160 ➝ GBX 1,200
i
5/8/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,200
i
5/8/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 1,345 ➝ GBX 1,280
i
5/5/2017Numis SecuritiesReiterated RatingAddGBX 1,350
i
5/5/2017The Goldman Sachs GroupReiterated RatingNeutralGBX 1,270
i
5/5/2017Jefferies Financial GroupReiterated RatingBuyGBX 1,350
i
5/5/2017Shore CapitalReiterated RatingHoldGBX 1,144
i
4/25/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,200
i
4/4/2017Numis SecuritiesReiterated RatingAddGBX 1,350
i
3/30/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,345
i
3/29/2017Jefferies Financial GroupReiterated RatingBuyGBX 1,350
i
3/21/2017Morgan StanleyReiterated RatingOverweight
i
3/1/2017JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,260 ➝ GBX 1,345
i
2/15/2017Berenberg BankLower Price TargetHoldGBX 1,340 ➝ GBX 1,275
i
2/13/2017Deutsche Bank AktiengesellschaftBoost Price TargetHoldGBX 1,150 ➝ GBX 1,200
i
2/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,260
i
2/10/2017Morgan StanleyReiterated RatingOverweightGBX 1,301
i
2/10/2017Jefferies Financial GroupLower Price TargetBuyGBX 1,370 ➝ GBX 1,350
i
2/9/2017Numis SecuritiesReiterated RatingAddGBX 1,350
i
2/8/2017Credit Suisse GroupReiterated RatingNeutralGBX 1,190
i
2/6/2017Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,150
i
2/6/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,260
i
1/18/2017Berenberg BankReiterated RatingHoldGBX 1,340
i
1/12/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,260
i
1/11/2017Morgan StanleyReiterated RatingOverweight
i
1/4/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,260
i
12/7/2016Jefferies Financial GroupLower Price TargetBuyGBX 1,395 ➝ GBX 1,370
i
12/2/2016Morgan StanleyReiterated RatingEqual weightGBX 1,249
i
12/2/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,260
i
11/25/2016The Goldman Sachs GroupLower Price TargetBuyGBX 1,370 ➝ GBX 1,310
i
11/22/2016UBS GroupReiterated RatingNeutralGBX 1,160
i
11/7/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,150
i
11/4/2016Jefferies Financial GroupLower Price TargetBuyGBX 1,420 ➝ GBX 1,395
i
11/4/2016Numis SecuritiesReiterated RatingAddGBX 1,350
i
11/1/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,199
i
11/1/2016Jefferies Financial GroupReiterated RatingBuyGBX 1,420
i
10/31/2016Credit Suisse GroupReiterated RatingNeutralGBX 1,285
i
10/26/2016Deutsche Bank AktiengesellschaftReiterated RatingHold
i
10/6/2016Berenberg BankDowngradeHoldGBX 1,485 ➝ GBX 1,340
i
9/14/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,199
i
9/13/2016The Goldman Sachs GroupReiterated RatingBuy
i
8/31/2016UBS GroupBoost Price TargetNeutralGBX 1,100 ➝ GBX 1,210
i
8/12/2016Jefferies Financial GroupReiterated RatingBuyGBX 1,420
i
8/10/2016BarclaysDowngradeEqual weightGBX 1,230 ➝ GBX 1,240
i
8/9/2016Beaufort SecuritiesReiterated RatingHold
i
8/2/2016The Goldman Sachs GroupLower Price TargetBuyGBX 1,410 ➝ GBX 1,370
i
8/2/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,150
i
7/29/2016Credit Suisse GroupReiterated RatingNeutralGBX 1,285
i
7/29/2016BNP ParibasReiterated RatingOutperformGBX 1,425
i
7/29/2016JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,196 ➝ GBX 1,199
i
7/28/2016Jefferies Financial GroupReiterated RatingBuyGBX 1,420
i
7/27/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 1,150
i
7/15/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 1,196
i
7/12/2016BNP ParibasReiterated RatingOutperformGBX 1,425
i
7/12/2016Berenberg BankBoost Price TargetBuyGBX 1,300 ➝ GBX 1,485
i
7/8/2016Credit Suisse GroupBoost Price TargetNeutralGBX 1,165 ➝ GBX 1,325
i
7/1/2016JPMorgan Chase & Co.Boost Price TargetNeutralGBX 1,096 ➝ GBX 1,196
i
6/30/2016Jefferies Financial GroupBoost Price TargetBuyGBX 1,375 ➝ GBX 1,420
i
6/27/2016BNP ParibasReiterated RatingOutperformGBX 1,335
i
6/24/2016Numis SecuritiesReiterated RatingAddGBX 1,242
i
(Data available from 6/17/2016 forward)
Smith & Nephew logo
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Read More

Today's Range

Now: GBX 1,549.50
1,544
1,558

50 Day Range

MA: GBX 1,506.75
1,396.50
1,583

52 Week Range

Now: GBX 1,549.50
1,317
1,681.50

Volume

996,272 shs

Average Volume

343,671 shs

Market Capitalization

£13.62 billion

P/E Ratio

42.57

Dividend Yield

1.79%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Smith & Nephew?

The following sell-side analysts have issued reports on Smith & Nephew in the last year: Barclays PLC, Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Shore Capital, and UBS Group AG.
View the latest analyst ratings for SN.

What is the current price target for Smith & Nephew?

6 Wall Street analysts have set twelve-month price targets for Smith & Nephew in the last year. Their average twelve-month price target is GBX 1,783, suggesting a possible upside of 15.1%. Berenberg Bank has the highest price target set, predicting SN will reach GBX 1,985 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 1,423 for Smith & Nephew in the next year.
View the latest price targets for SN.

What is the current consensus analyst rating for Smith & Nephew?

Smith & Nephew currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SN will outperform the market and that investors should add to their positions of Smith & Nephew.
View the latest ratings for SN.

What other companies compete with Smith & Nephew?

How do I contact Smith & Nephew's investor relations team?

Smith & Nephew's physical mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company's listed phone number is +44-20-74017646. The official website for Smith & Nephew is www.smith-nephew.com.